Kofimi Technology

Executive Summary

Kofimi Technology is an early-stage medical device company based in San Francisco, founded in 2019, that is developing ChromaSense™, an AI-powered next-generation pulse oximeter designed to deliver high-precision, bias-free blood oxygen readings across diverse patient populations. The company addresses a critical flaw in current pulse oximetry technology, which has been shown to overestimate oxygen saturation in individuals with darker skin tones, leading to disparities in clinical care. By leveraging machine learning algorithms that account for variations in skin pigmentation, ChromaSense™ aims to provide accurate readings for all patients, thereby improving diagnostic equity and patient outcomes in settings ranging from hospital wards to remote monitoring. The company operates at the intersection of digital health, AI, and diagnostics, and is positioned to capitalize on increasing regulatory and clinical focus on health equity. While Kofimi Technology is still in the early stages, its technology has the potential to disrupt the pulse oximetry market, which is dominated by legacy devices with known biases. Key upcoming catalysts include FDA 510(k) clearance for ChromaSense™, initial clinical validation studies, and potential partnerships with major health systems or value-based care providers. Given the clear unmet need and growing awareness of racial bias in medical devices, Kofimi Technology has strong growth potential, though execution risks remain until regulatory milestones are achieved.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for ChromaSense™ pulse oximeter60% success
• Q3 2026Publication of clinical validation study results demonstrating bias-free performance across skin tones70% success
• Q1 2027Strategic partnership or pilot program with a major U.S. hospital system50% success